Member Info for emptyend

Thanks for the feedback/comments. There was one they were particularly holding back on, to partner on better terms - was it this one?

Re Thailand, this is the 7th holiday visit, tf., ....so have done all the obvious. This time it is Pranburi.....a steady 34 degrees and full sun and a stiff onshore breeze to make it extremely pleasant!

More Thursday I guess....ie the presentation with the preclinical data.

I'm currently in Thailand with no access to my written notes. Was this the antibody they were keen to hold back on?

Not long to wait now until we get to see who has been selling her shares to Brad without notifying the market......the AR&A list comes from company inspection of the share register, and so by-passes the notification process.

.....and then it will start to get interesting....

Well yes, I would have changed BDO too if there was the slightest chance of a repeat.

The thought also occurs to me (having looked into RSM rather more) that RSM may have a rather more significant footprint in USA than BDO? That might be relevant for the end-game here?

Ipad, Thanks for confirming that. But is still feels to me that there is more to it, in part because as tf correctly notes, RSM is much smaller than BDO. i assume there is some sort of connection with the new CFO.

Though of course it is best practice to put audits out to tender from time to time and I guess the trigger might have been that BDO were planning to switch audit partner anyway.

When you raised it at the AGM, did you get a steer on what had happened? It was indeed highly inopportune timing and unhelpful to the share price but I had thought at the time that it was likely to be a personal issue involving the audit partner. Today’s announcement looks to indicate that it might have been a very avoidable delay in the accounts which was actually the fault of BDO.

Indeed it looks like immediate action was taken to replace the auditor, given the time it usually takes to run and determine a competitive process.

Remember that Viagra became a top seller for Pfizer because its side effects were more interesting than its actual objective. 😏

Perhaps T-cells can be targeted at eliminating body fat……? 😬

Re unknown unknowns, that is precisely the way Modi-1 appeared. Listen to the Goodfellow interview.

There are known knowns (which you focus on), known unknowns (which many others highlight),…..and unknown unknowns.

The history of Scancell suggests the latter shouldn’t be ignored.

No surprise. The London market is cooking its own goose as a capital-raising centre, thanks in large part to the burden imposed by woke groupthink which has, over the last decade, killed the capacity of oil and gas or mining businesses to raise money - and the consequent move to risk aversion is causing biotech and tech companies to vote with their feet and go to New York.

Neither do I, WTP.

Just a small correction. There are five companies seeking exclusivity - but they are unlikely to be “competing” with each other (not all of them, anyway).

That is also a question that had occurred to me. I assume so. However, he seems to have passed things to his son?

Stamp took an active role in the only AGM I’ve attended to date.

😂😂

One thing that can be guaranteed is that there would be no such statement, especially at the outset of the treatment. And it is highly improbable that the King would turn up on, for example, the renal arm of the Mod1fy trial.

If I were to put money on it, I’d guess it may be a personalised vaccine…..but that itself may be quite encouraging for the vaccine space.

Neverthess, his medical adviser works through Imperial - which is one of the Modi-1 trial centres…….so it isn’t a total impossibility.

I noticed that this week Barry Sheerman MP called for a Commons debate on advances in cancer care, including immunotherapy:

https://www.theyworkforyou.com/debates/?id=2024-02-08a.375.0

He was invited to apply for such a debate by Penny Mordaunt, and so it seems probable that this will happen in the next couple of months. I would hope that Scancell will ensure that the case for investing in and promoting DNA vaccines is highlighted, so that MPs don’t just assume that mRNA, Moderna etc etc is the only game in town!

Ruck,

I’d like to agree with you and WTP. But am troubled by the point I noted earlier…

“ Seems to be an excessive focus on mRNA personalised vaccines…..” and I am also reminded of certain larger companies being given the inside track on Covid vaccines. mRNA technology still seems strongly favoured, despite various reservations.

WTP,

Of course there are differences. But market heft remains crucial. There is little doubt that if Scancell’s IP was in the hands of a more substantial company, it could be developed more quickly.

Perhaps that will happen?

The VHS/Betamax analogy is a good one. I would also make a comparison with WordPerfect and Word.

In both cases, (arguably) better technical solutions failed to get market traction because they were later than the other and because the weaker technical solutions had more market heft.

Which is which here?

Seems to be an excessive focus on mRNA personalised vaccines…..